Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobal Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
- Dental Equipment Market Forecasts Growth from $8.31B (2026) to $11.48B by 2031, Profiling Envista, Carestream Dental, Nakanishi & Dentsply SironaThe global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec.
- Dental Consumables Market Forecasts Growth from $37.0B (2026) to $54.0B by 2031, Profiling Institut Straumann, Envista, Dentsply Sirona & 3MCompanies: 3MThe global dental consumables market is projected to grow from USD 37.0 billion in 2026 to USD 54.0 billion by 2031, registering a 7.9% CAGR. Growth is driven by rising dental disease prevalence, aging populations, cosmetic dentistry demand, improved access to oral care, and adoption of digital dentistry and CAD/CAM technologies. Dental restoration leads by product type, while dental hospitals and clinics hold the largest end-user share. Asia Pacific is expected to record the highest CAGR, supported by expanding healthcare infrastructure, rising incomes, and greater oral health awareness.
- transcosmos inc.Toward a new era of pharmaceutical education: TUPLS and transcosmos launch a co-development project to build an AI-powered, dialogue-based learning platformAdvancing support for foundational learning, patient communication, and continuous learning in clinical pharmaceutical education TOKYO, Sept. 30, 2026/PRNewswire/ -- The Tokyo University of Pharmacy and Life Science (Location: Tokyo, Japan; President: Yoshihiro Mimaki; TUPLS) and...
- Newronika S.p.A.Newronika Announces First Participant Implanted in ADVENT Pivotal StudyMilestone initiates Newronika's international pivotal study comparing adaptive and conventional deep brain stimulation for Parkinson's disease — Newronika S.p.A., a medical technology company developing adaptive deep brain stimulation therapies, today...
- Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society CongressItalfarmaco S.p.A. today announced new long-term data from the ongoing Phase 3 EPIDYS open-label extension (OLE) study showing that treatment with givinostat (Duvyzat®) may help preserve upper limb function in boys with Duchenne muscular dystrophy (DMD). The findings, presented at the 31st Annual International Congress of the World Muscle Society (WMS), provide further evidence supporting the long-term clinical benefits of givinostat across multiple measures of disease progression. John Brandsema, MD, Paediatric Neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, presented the poster "Trajectory of Performance of Upper Limb in Patients With Duchenne Muscular Dystrophy Treated With Givinostat Relative to a Modeled Natural History Cohort from a Single Centre," which compared upper limb function in givinostat-treated patients with counterfactual trajectories estimated from an external natural history-based model representing predicted disease progression in the absence of treatment, using the Performance of Upper Limb 2.0 (PUL 2.0) assessment. Upper limb function is an increasingly important measure of disease progression as DMD advances and loss of ambulation occurs. “Preserving upper limb function is critically important for people living with Duchenne because it directly affects independence and the ability to perform everyday activities,” said Scott Baver, PhD, VP, Head of Global Medical Affairs, Rare Diseases. “These new findings extend our understanding of givinostat beyond ambulatory outcomes and provide exploratory evidence suggesting a potential effect on the preservation of upper limb function, an important aspect of disease progression for people living with DMD.” “Upper limb function becomes increasingly important as Duchenne progresses because it has a direct impact on independence and participation in daily life,” said John Brandsema, MD, Paediatric Neurologist at Children’s Hospital of Philadelphia and presenter of the analysis. “Preserving upper limb function is an outcome that matters greatly to patients and families.” Key findings: These exploratory analyses compared observed outcomes in patients receiving givinostat with predicted outcomes generated from an external natural history-based model and should be interpreted within the context of this study design.
- Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell CancersHummingbird Bioscience announced that the first patient has been dosed in Phase II trial of HMBD-001 and cetuximab in advanced squamous cell cancers.
- ENT & Allergy Associates Expands Pennsylvania Footprint with Melissa Schwartz, DO, and New Elkins Park Clinical SiteENT & Allergy Associates of Pennsylvania today announced the addition of otolaryngologist Melissa Schwartz, DO, and her established clinical practice at 375 Township Line Road in Elkins Park, PA, effective January 1, 2027.
- North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion OpportunityTarget clinical and biopharma segments, forge strategic partnerships, and differentiate with scalable, low-toxicity delivery solutions.
- Pacemaker/Defibrillator Lead Extraction Kit Market Forecast - 2034 | $1.92 Billion Opportunity Fueled by Minimally Invasive Care and Rising CIED InfectionsPrioritize capital-free mechanical systems and hospital lead-management programs; expand in Asia-Pacific as CIED use and cardiac infrastructure rise.
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CarePrioritize HPV16-targeted vaccines, checkpoint inhibitor combinations and biomarker-led patient selection to overcome resistance and capture underserved HNSCC segments.
- Artificial Intelligence (AI) in Life Sciences Market: Trends and Forecast to 2040 | Market to Reach USD 73.05 Billion at 20% CAGR as Drug Discovery and Precision Medicine ScaleAI boosts life sciences ROI by accelerating drug discovery, reducing R&D costs, optimizing clinical trials and enabling precision medicine through strategic tech partnerships.